HIGHLIGHTS
- who: Erik from the University have published the paper: Title: Interleukin-1 receptor-associated kinase-3 acts as an immune checkpoint in, in the Journal: (JOURNAL)
- what: Altogether the study demonstrated a novel cancer-driven immune tolerance program controlled by IRAK3 in humans and mice and proposed its suitability as an immunotherapy target. Because IRAK3 mRNA expression is associated with patient response to immunotherapy in the analysis , the authors investigated the putative underlying mechanisms of IRAK3 in human primary monocytes using CRISPR/Cas9 genome editing. The authors show here that the pre- therapy IRAK3 level . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.